Neurostimulation
-
Neuro
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation System™
U.S. patients implanted with ReActiv8 now eligible for full-body MRI scans DUBLIN, February 12, 2024–(BUSINESS WIRE)–Mainstay Medical Holdings plc today…
Read More » -
Spine
Mainstay Medical Announces Publication of Two-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™
Data shows compelling efficacy and safety, as well as improvement on all key measures of pain and disability as compared…
Read More » -
Neuro
Mainstay Medical Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain
June 22, 2020 DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced that the U.S. Food and Drug…
Read More » -
Neuro
SurGenTec® Announces FDA Clearance for Neurostimulation with ALARA™ Access Needle Kit
August 22, 2019 BOCA RATON, Fla.–(BUSINESS WIRE)–SurGenTec, a privately held spine and orthopedic technology company, announced today it has received…
Read More » -
Financial
Spinal Intervention: Markets for Surgical, Replacement & Neurostimulation Technologies – Research and Markets
December 16, 2016 DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Spinal Intervention: Markets for Surgical, Replacement and…
Read More »